Opioid use disorder
Top Cited Papers
- 9 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Disease Primers
- Vol. 6 (1), 1-28
- https://doi.org/10.1038/s41572-019-0137-5
Abstract
Opioid use disorder (OUD) is a chronic relapsing disorder that, whilst initially driven by activation of brain reward neurocircuits, increasingly engages anti-reward neurocircuits that drive adverse emotional states and relapse. However, successful recovery is possible with appropriate treatment, although with a persisting propensity to relapse. The individual and public health burdens of OUD are immense; 26.8 million people were estimated to be living with OUD globally in 2016, with >100,000 opioid overdose deaths annually, including >47,000 in the USA in 2017. Well-conducted trials have demonstrated that long-term opioid agonist therapy with methadone and buprenorphine have great efficacy for OUD treatment and can save lives. New forms of the opioid receptor antagonist naltrexone are also being studied. Some frequently used approaches have less scientifically robust evidence but are nevertheless considered important, including community preventive strategies, harm reduction interventions to reduce adverse sequelae from ongoing use and mutual aid groups. Other commonly used approaches, such as detoxification alone, lack scientific evidence. Delivery of effective prevention and treatment responses is often complicated by coexisting comorbidities and inadequate support, as well as by conflicting public and political opinions. Science has a crucial role to play in informing public attitudes and developing fuller evidence to understand OUD and its associated harms, as well as in obtaining the evidence today that will improve the prevention and treatment interventions of tomorrow.Keywords
This publication has 275 references indexed in Scilit:
- Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs Oral Naltrexone or Placebo for Preventing Relapse to Opioid DependenceArchives of General Psychiatry, 2012
- Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid DependenceArchives of General Psychiatry, 2011
- Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related ConditionsPsychological Medicine, 2011
- Evaluating the drug use "gateway" theory using cross-national data: Consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health SurveysDrug and Alcohol Dependence, 2010
- Child maltreatment as a risk factor for opioid dependence: Comparison of family characteristics and type and severity of child maltreatment with a matched control groupChild Abuse & Neglect, 2009
- The α1 adrenergic receptor antagonist prazosin reduces heroin self-administration in rats with extended access to heroin administrationPharmacology Biochemistry and Behavior, 2009
- Real-Time Electronic Diary Reports of Cue Exposure and Mood in the Hours Before Cocaine and Heroin Craving and UseArchives of General Psychiatry, 2009
- Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadoneDrug and Alcohol Dependence, 2007
- The amygdala: Different pains, different mechanismsPain, 2007
- Is there a common molecular pathway for addiction?Nature Neuroscience, 2005